An In Vivo Mouse Model of Pelvic Recurrence of Human Colorectal Cancer.

An In Vivo Mouse Model of Pelvic Recurrence of Human Colorectal Cancer.
复制标题

人类结直肠癌盆腔复发的体内小鼠模型。

DOI:
10.1038/s41598-019-56152-0
复制
发表时间:
2019
期刊:
Sci Rep.
影响因子:
--
通讯作者:
Uchiyama K.
Uchiyama K.
中科院分区:
--
文献类型:
--
作者:
Yamamoto M;Masubuchi S;Taniguchi K;Tominaga T;Inomata Y;Miyamoto A;Ishizuka T-A;Murakami T;Osumi W;Hamamoto H;Tanaka K;Okuda J;Uchiyama K.

文献摘要

相似文献

盆腔复发是结直肠癌的一个关键问题,因为根治性手术可能导致过度侵袭。需要新的治疗策略来代替手术。然而,由于骨盆内肿瘤的移植和观察困难,适合的模型很少。我们已经建立了一个合适的注射部位,适合建立结直肠癌盆腔复发,允许观察肿瘤生长。将稳定表达荧光素酶的DLD-1细胞(DLD-1克隆#1-Luc)接种于雌性BALB/c裸鼠的不同部位,利用生物发光信号成像系统和计算机断层成像系统对移植细胞进行分析。每周用成像系统分析显示,阴道、肛门和坐骨棘界定的三角形区域适合盆腔肿瘤的植入。该成像系统能够在接种细胞7天后检测到植入的肿瘤。在我们的模型中观察到体重减轻,总生存期为21-42天。组织病理学检查发现肿瘤累及邻近器官,临床情况也是如此。这些发现表明,该模型对于评估正在开发的新疗法的治疗效果是有效的。希望该模型能用于临床前研究。
Pelvic recurrence of colorectal cancer is a crucial problem because radical surgery can lead to excessive invasion. Novel therapeutic strategies are required instead of surgery. However, there are few suitable models because of the difficulty in transplanting and observing tumors in the pelvis. We have established an appropriate injection site suitable for the establishment of colorectal cancer pelvic recurrence that allows for the observation of tumor growth. DLD-1 cells stably expressing luciferase (DLD-1 clone#1-Luc) were inoculated into various points of female BALB/c nude mice and the engrafted cells were analyzed with an imaging system employing bioluminescent signals and computed tomography. Weekly analysis with the imaging system showed that a triangular area defined by the vagina, the anus, and the ischial spine was suitable for the engraftment of pelvic tumors. The imaging system was able to detect the engrafted tumor 7 days after the inoculation of cells. Weight loss was observed in our model, and overall survival was 21–42 days. Tumor involvement of adjacent organs was detected histopathologically, as is the case in the clinical situation. These findings suggest that this model is valid for evaluations of the therapeutic effects of novel treatments under development. It is hoped that this model will be used in preclinical research.